(Q37568164)

21 August 2017

1 reference

title

Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins (English)

1 reference

21 August 2017

Verstraete M

1

1 reference

21 August 2017

1 October 1990

1 reference

21 August 2017

1 reference

21 August 2017

40

1 reference

21 August 2017

498-530

1 reference

21 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199040040-00003

21 August 2017

0 references

cites work

Hickman catheter use in a pregnant patient requiring therapeutic heparin anticoagulation

1 reference

12 December 2020

Fractionation of low molecular weight heparin species and their interaction with antithrombin

1 reference

12 December 2020

Prophylaxis of postoperative thromboembolism with low dose heparin alone or in combination with dihydroergotamine. A review

1 reference

12 December 2020

Heparin-induced osteoporosis in rats

1 reference

12 December 2020

Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis

1 reference

12 December 2020

Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin

1 reference

12 December 2020

The antithrombin-binding sequence in heparin. Identification of an essential 6-O-sulfate group

1 reference

12 December 2020

Binding of heparin on the surface of cultured human endothelial cells

1 reference

12 December 2020

Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial

1 reference

12 December 2020

Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism.

1 reference

12 December 2020

Cardiopulmonary bypass with a low-molecular-weight heparin fraction.

1 reference

12 December 2020

A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time

1 reference

12 December 2020

Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina

1 reference

12 December 2020

Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection

1 reference

12 December 2020

Neutralisation of heparan sulphate and low molecular weight heparin by protamine.

1 reference

12 December 2020

Heparin elimination in patients with liver cirrhosis

1 reference

12 December 2020

Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study

1 reference

12 December 2020

Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).

1 reference

12 December 2020

Heparin and platelet function

1 reference

12 December 2020

Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers

1 reference

12 December 2020

Efficacy of low-dose, subcutaneously administered heparin in treatment of pregnant women with artificial heart valves

1 reference

12 December 2020

The natural history of lone atrial fibrillation. A population-based study over three decades

1 reference

12 December 2020

Local tolerance of subcutaneous heparin. Double-blind comparison of calcium and sodium heparins (author's transl)

1 reference

12 December 2020

Heparin 1986. Indications and effective use.

1 reference

12 December 2020

A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery

1 reference

12 December 2020

The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Further characterization of the antithrombin-binding sequence in heparin

1 reference

12 December 2020

Plasma heparin levels after administration of calcium and sodium salts of heparin

1 reference

12 December 2020

Binding and endocytosis of heparin by human endothelial cells in culture

1 reference

12 December 2020

Release of LPL activity after intravenous injection of a low molecular weight heparin

1 reference

12 December 2020

Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin.

1 reference

12 December 2020

Small doses of heparin and a new concept of hypercoagulability

1 reference

12 December 2020

A collaborative study designed to establish the 4th International Standard for Heparin.

1 reference

12 December 2020

Thrombosis and thrombocytopenia induced by heparin

1 reference

12 December 2020

Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser

1 reference

12 December 2020

Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.

1 reference

12 December 2020

Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis.

1 reference

12 December 2020

[Thrombopenia caused by fraxiparin. A case]

1 reference

12 December 2020

Catabolism of low-dose heparin in man

1 reference

12 December 2020

The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

1 reference

12 December 2020

Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Heparin pharmacokinetics: increased requirements in pulmonary embolism

1 reference

12 December 2020

Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis

1 reference

12 December 2020

Quantitative aspects of antithrombin and heparin in plasma

1 reference

12 December 2020

Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications

1 reference

12 December 2020

Evidence for a saturable mechanism of disappearance of standard heparin in rabbits

1 reference

12 December 2020

Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously.

1 reference

12 December 2020

[In vitro and in vivo neutralisation of a low molecular weight heparin fraction CY 216 by protamine]

1 reference

12 December 2020

Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group

1 reference

12 December 2020

The effect of molecular weight on the bioavailability of heparin.

1 reference

12 December 2020

Heparin-associated thrombocytopenia: alternative managements

1 reference

12 December 2020

Lipolytic enzymes and plasma lipoprotein metabolism

1 reference

12 December 2020

Highly Purified Antithrombin III with Heparin Cofactor Activity Prepared by Disc Electrophoresis

1 reference

12 December 2020

Are molecular weight and anti-Xa activity sufficient to predict the antithrombotic power of heparin fractions.

1 reference

12 December 2020

Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction

1 reference

12 December 2020

Low-molecular-weight heparin: is small beautiful?

1 reference

12 December 2020

The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement.

1 reference

12 December 2020

Heparin-induced platelet aggregation: dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions

1 reference

12 December 2020

Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma

1 reference

12 December 2020

Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges

1 reference

12 December 2020

A proteoglycan form of heparin and its degradation to single-chain molecules

1 reference

12 December 2020

Antithrombin III and heparin

1 reference

12 December 2020

Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty

1 reference

12 December 2020

The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits.

1 reference

12 December 2020

[Efficacy and tolerance of low molecular weight heparin in the prevention of deep venous thrombosis during non-emergent total hip arthroplasty. A prospective, multicenter trial]

1 reference

12 December 2020

[Effectiveness of low molecular weight heparin (Fragmin) in the prevention of thromboembolism in internal medicine patients. A randomized double-blind study]

1 reference

12 December 2020

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

1 reference

12 December 2020

Detection of a new heparin-dependent inhibitor of thrombin in human plasma

1 reference

12 December 2020

Pregnancy in patients with prosthetic heart valves: an experience with 45 pregnancies.

1 reference

12 December 2020

Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity

1 reference

12 December 2020

Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure

1 reference

12 December 2020

Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement

1 reference

12 December 2020

Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis.

1 reference

12 December 2020

Effectiveness of low-dose heparin in prevention of myocardial reinfarction.

1 reference

12 December 2020

A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.

1 reference

12 December 2020

Properties of the factor Xa binding site on human platelets

1 reference

12 December 2020

The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor

1 reference

12 December 2020

Optimum use of anticoagulants in pregnancy

1 reference

12 December 2020

The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis.

1 reference

12 December 2020

Effect of Heparin and Heparin Fractions on Platelet Aggregation

1 reference

12 December 2020

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

1 reference

12 December 2020

Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and a low molecular-weight heparin

1 reference

12 December 2020

The Purification and Mechanism of Action of Human Antithrombin-Heparin Cofactor

1 reference

12 December 2020

Heparin-lipoprotein lipase interactions

1 reference

12 December 2020

Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study.

1 reference

12 December 2020

The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin

1 reference

12 December 2020

Arginine residues are critical for the heparin-cofactor activity of antithrombin III.

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Structural studies on a biologically active hexasaccharide obtained from heparin

1 reference

12 December 2020

Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.

1 reference

12 December 2020

Changes in plasma antithrombin (heparin cofactor activity) during intravenous heparin therapy: observations in 198 patients with deep venous thrombosis

1 reference

12 December 2020

Effect of early anticoagulation on the frequency of left ventricular thrombi after anterior wall acute myocardial infarction

1 reference

12 December 2020

Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients.

1 reference

12 December 2020

Differential anticoagulant activity of heparin fragments prepared using microbial heparinase

1 reference

12 December 2020

A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism

1 reference

12 December 2020

Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.

1 reference

12 December 2020

An overview of clinical trials of low molecular weight heparin fractions.

1 reference

12 December 2020

Atherogenic regulation by heparin-like molecules

1 reference

12 December 2020

Dosage in Low-Dose Heparin Prophylaxis

1 reference

12 December 2020

Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction

1 reference

12 December 2020

Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.

1 reference

12 December 2020

Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin

1 reference

12 December 2020

A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin

1 reference

12 December 2020

Two-substrate reaction model for the heparin-catalyzed bovine antithrombin/protease reaction.

1 reference

12 December 2020

Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy

1 reference

12 December 2020

Kinetics of intravenously administered heparin in normal humans

1 reference

12 December 2020

The elimination from plasma of intravenous heparin. An experimental study on dogs and humans

1 reference

12 December 2020

Antiheparin activity in human endothelial cells

1 reference

12 December 2020

Suppression of aldosterone production by low-dose heparin

1 reference

12 December 2020

Anticoagulants in venous thromboembolism

1 reference

12 December 2020

Partially N-desulfated heparin as a non-anticoagulant heparin: some physico-chemical and biological properties

1 reference

12 December 2020

Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients

1 reference

12 December 2020

[Evaluation of the prevention of perioperative thromboembolism with low molecular weight heparin and dihydroergotamine. A study of the incidence of lethal pulmonary embolisms and undesired symptoms, especially the risk of vasospasm and myocardial in

1 reference

12 December 2020

The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity

1 reference

12 December 2020

Heparin and dihydroergotamine prophylaxis against thrombo-embolism after hip arthroplasty

1 reference

12 December 2020

Cooperative study on the value of long term anticoagulation in patients with stroke and non-rheumatic atrial fibrillation

1 reference

12 December 2020

The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model

1 reference

12 December 2020

Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III.

1 reference

12 December 2020

Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).

1 reference

12 December 2020

Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin.

1 reference

12 December 2020

Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction

1 reference

12 December 2020

Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study

1 reference

12 December 2020

Comparative plasma heparin levels after subcutaneous sodium and calcium heparin

1 reference

12 December 2020

Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals

1 reference

12 December 2020

A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.

1 reference

12 December 2020

Inducing hyperkalemia by converting enzyme inhibitors and heparin

1 reference

12 December 2020

A low molecular weight heparin compared with unfractionated heparin.

1 reference

12 December 2020

[Prevention of deep venous thrombosis in orthopedic surgery for total hip prosthesis. Randomized trial for determining optimal dosage]

1 reference

12 December 2020

A meta-analysis of the studies of dihydroergotamine plus heparin in the prophylaxis of deep vein thrombosis.

1 reference

12 December 2020

Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits.

1 reference

12 December 2020

Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fraction

1 reference

12 December 2020

Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction.

1 reference

12 December 2020

The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombus

1 reference

12 December 2020

Heparin flushes and thrombocytopenia

1 reference

12 December 2020

Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography

1 reference

12 December 2020

[Use of low molecular-weight heparin in hemodialysis patients]

1 reference

12 December 2020

An evaluation of APTT monitoring of low-dose heparin dosage in hip surgery

1 reference

12 December 2020

Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients.

1 reference

12 December 2020

Kinetic study of tPA release induced by heparin and heparin fragment

1 reference

12 December 2020

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery

1 reference

12 December 2020

SYSTEMIC EMBOLISM AND ANTICOAGULANT PROPHYLAXIS IN RHEUMATIC HEART DISEASE.

1 reference

12 December 2020

Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis.

1 reference

12 December 2020

Thrombosis prophylaxis with low molecular weight heparin in total hip replacement.

1 reference

12 December 2020

Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound.

1 reference

12 December 2020

Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris

1 reference

12 December 2020

1 reference

12 December 2020

Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex.

1 reference

12 December 2020

Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis

1 reference

12 December 2020

The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III

1 reference

12 December 2020

Heparin cofactor II in patients with deep venous thrombosis under heparin and oral anticoagulant therapy

1 reference

12 December 2020

Propylene glycol-induced heparin resistance during nitroglycerin infusion.

1 reference

12 December 2020

Low incidence of thrombocytopenia with porcine mucosal heparin. A prospective multicenter study

1 reference

12 December 2020

[Clinical tolerance of CY 216 (Fraxiparin) in the prevention of thromboembolic accidents after neurosurgery]

1 reference

12 December 2020

Studies in man and experimental animals of a low molecular weight heparin fraction

1 reference

12 December 2020

Duration of anticoagulant therapy in venous thrombo--embolism

1 reference

12 December 2020

Characterization of platelet binding of heparins and other glycosaminoglycans

1 reference

12 December 2020

A low molecular weight heparin alters the fetal coagulation system in the pregnant sheep.

1 reference

12 December 2020

Fibrinolytic therapy of acute myocardial infarction in the heparin thrombosis syndrome

1 reference

12 December 2020

Biologicals, standards and heparin

1 reference

12 December 2020

The relationship of molecular weight, and sulfate content and distribution to anticoagulant activity of heparin preparations

1 reference

12 December 2020

The use of low molecular weight heparins for postsurgical deep vein thrombosis prevention in orthopaedic patients.

1 reference

12 December 2020

Profibrinolytic activities of chemically modified heparins with very low anticoagulant activities

1 reference

12 December 2020

Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers

1 reference

12 December 2020

A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.

1 reference

12 December 2020

Immediate anticoagulation of embolic stroke: a randomized trial. Cerebral Embolism Study Group

1 reference

12 December 2020

Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis

1 reference

12 December 2020

Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits

1 reference

12 December 2020

Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III.

1 reference

12 December 2020

Heparin-induced thrombocytopenia: further studies of the effects of heparin-dependent antibodies on platelets

1 reference

12 December 2020

The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.

1 reference

12 December 2020

Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis.

1 reference

12 December 2020

Interaction of heparin and antithrombin III. The role of O-sulfate groups

1 reference

12 December 2020

Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation

1 reference

12 December 2020

Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. The SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group

1 reference

12 December 2020

Binding of active and inactive forms of lipoprotein lipase to heparin. Effects of pH.

1 reference

12 December 2020

Heparin-induced thrombocytopenia

1 reference

12 December 2020

Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats.

1 reference

12 December 2020

Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions.

1 reference

12 December 2020

In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine.

1 reference

12 December 2020

Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement

1 reference

12 December 2020

One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis.

1 reference

12 December 2020

Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional echocardiographic study of 119 patients

1 reference

12 December 2020

Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro.

1 reference

12 December 2020

Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III

1 reference

12 December 2020

Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis

1 reference

12 December 2020

Allergic thrombopenia induced by heparin or pentosan polysulfate

1 reference

12 December 2020

Low molecular weight heparin (Logiparin) as thromboprophylaxis in elective abdominal surgery. A dose finding study.

1 reference

12 December 2020

Thrombolysis with a Combination of Small Doses of Streptokinase and Full Doses of Heparin

1 reference

12 December 2020

Management of heparin therapy: Controlled prospective trial

1 reference

12 December 2020

Interactions between heparin and factor Xa inhibition of prothrombin activation

1 reference

12 December 2020

Intravenous heparin for the prevention of stroke progression in acute partial stable stroke

1 reference

12 December 2020

Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration.

1 reference

12 December 2020

Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo

1 reference

12 December 2020

Endothelial binding sites for heparin. Specificity and role in heparin neutralization

1 reference

12 December 2020

Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids

1 reference

12 December 2020

Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty

1 reference

12 December 2020

Biosynthesis of heparin. Assay and properties of the microsomal uronosyl C-5 epimerase

1 reference

12 December 2020

Immediate effects of heparin and LMW heparin on some platelet and endothelial derived factors

1 reference

12 December 2020

Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His.

1 reference

12 December 2020

Heparin-induced decrease in circulating antithrombin-III.

1 reference

12 December 2020

Fibrinolytic and thrombolytic parameters in patients with deep vein thrombosis treated by low molecular weight and standard heparin

1 reference

12 December 2020

Multiple functional domains of the heparin molecule

1 reference

12 December 2020

Treatment of pulmonary embolic disease. A critical review of some aspects of current therapy

1 reference

12 December 2020

The observation of heparin on endothelium after injection

1 reference

12 December 2020

Vascular sequestration of heparin

1 reference

12 December 2020

In vitro protamine neutralization profiles of heparins differing in source and molecular weight

1 reference

12 December 2020

[Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery]

1 reference

12 December 2020

An international standard for low molecular weight heparin.

1 reference

12 December 2020

Synthesis and Properties of Heparin Derivatives

1 reference

12 December 2020

Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial.

1 reference

12 December 2020

Prophylaxis for postoperative deep-vein thrombosis. Synergistic effect of heparin and dihydroergotamine

1 reference

12 December 2020

Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial.

1 reference

12 December 2020

Structure and biosynthesis of heparin-like polysaccharides

1 reference

12 December 2020

An objective study of alternative methods of heparin administration

1 reference

12 December 2020

Heparin-associated thrombocytopenia and thrombosis

1 reference

12 December 2020

Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides

1 reference

12 December 2020

The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.

1 reference

12 December 2020

Modifications of liver enzymes during heparin therapy

1 reference

12 December 2020

Heparin degradation in the endothelial cells

1 reference

12 December 2020

[Comparison of the efficacy and tolerance of Kabi 2165 and standard heparin in the prevention of deep venous thrombosis in total hip prosthesis]

1 reference

12 December 2020

Immune endothelial-cell injury in heparin-associated thrombocytopenia

1 reference

12 December 2020

Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement

1 reference

12 December 2020

Prevention of thromboembolism in hysterectomies with low molecular weight heparin Fragmin

1 reference

12 December 2020

Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity

1 reference

12 December 2020

Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group

1 reference

12 December 2020

The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence

1 reference

12 December 2020

Heparin, brain thromboplastin and the insensitivity of the prothrombin time to heparin activity

1 reference

12 December 2020

Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis.

1 reference

12 December 2020

A disulfide bond in antithrombin is required for heparin-accelerated thrombin inactivation

1 reference

12 December 2020

Heparin-induced hyperlipidemia in a patient with pre-existing dysbetalipoproteinemia

1 reference

12 December 2020

Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Cerebral Embolism Study Group

1 reference

12 December 2020

Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis

1 reference

12 December 2020

Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine.

1 reference

12 December 2020

Standardization of low molecular weight heparins: a collaborative study

1 reference

12 December 2020

Thrombopenia under low molecular weight heparin after treatment with pentosan polyphosphate

1 reference

12 December 2020

A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial

1 reference

12 December 2020

Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity.

1 reference

12 December 2020

Protection of factor Xa from neutralization by the heparin-antithrombin complex

1 reference

12 December 2020

Studies on the Antithrombin and Heparin Co-factor Activities of a Fraction Adsorbed from Plasma by Aluminum Hydroxide

1 reference

12 December 2020

The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin

1 reference

12 December 2020

Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

1 reference

12 December 2020

Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis

1 reference

12 December 2020

Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis

1 reference

12 December 2020

Effect of low-molecular-weight heparins on laser-induced thrombus formation in rat mesenteric vessels

1 reference

12 December 2020

Disseminated coronary thrombosis and thrombopenia induced by pentosan polysulfate

1 reference

12 December 2020

Thromboembolism and antithrombotic therapy in peripheral arterial disease

1 reference

12 December 2020

Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats

1 reference

12 December 2020

Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats

1 reference

12 December 2020

Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction

1 reference

12 December 2020

Randomised trial of fish oil for prevention of restenosis after coronary angioplasty

1 reference

12 December 2020

Structural features of heparin and their effect on heparin cofactor II mediated inhibition of thrombin

1 reference

12 December 2020

Thrombolytic therapy in heparin-associated thrombocytopenia with thrombosis.

1 reference

12 December 2020

10.2165/00003495-199040040-00003

Identifiers

DOI

1 reference

PubMed ID

1964634

Dimensions Publication ID

21 August 2017

0 references

1 reference

PubMed ID

1964634